| Previous Close | 0.1050 |
| Open | 0.1100 |
| Bid | 0.1000 x N/A |
| Ask | 0.1100 x N/A |
| Day's Range | 0.1100 - 0.1100 |
| 52 Week Range | 0.0800 - 0.4500 |
| Volume | 1,000 |
| Avg. Volume | 73,713 |
| Market Cap | 7.16M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0160 |
| Earnings Date | Apr. 23, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
Pascal Biosciences Announces Management Changes
VANCOUVER, BC / ACCESSWIRE / March 22, 2021 / Pascal Biosciences Inc. ("Pascal" or the "Company") (TSXV:PAS)(OTC PINK:BIMUF), a biotechnology company that specializes in cancer, cannabinoids, and Covid-19 is announcing several management changes following its recent capital raise.
- ACCESSWIRE
Pascal Biosciences Inc. Closes Second Tranche of Non-Brokered Private Placement of $750,000
NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVANCOUVER, BC / ACCESSWIRE / March 17, 2021 / Pascal Biosciences Inc. ("Pascal" or the "Company") (TSXV:PAS)(OTC PINK:BIMUF), a biotechnology company that specializes in cancer, cannabinoids, and Covid-19 is pleased to announce the closing of the second tranche of the non-brokered private placement announced on November 2, 2020, January 19, 2021 and January 22, 2021 (the "Private Placement").
- ACCESSWIRE
Pascal Biosciences to Present at Cannabinoid Derived Pharmaceuticals Industry Review Summit
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / January 21, 2021 / Pascal Biosciences, Inc. ("Pascal" or the "Company") (TSXV:PAS)(OTC PINK:BIMUF), will present at the first Cannabinoid Derived Pharmaceuticals Industry Review Summit today.
